[{"id":"2617ca5f-47d4-4a37-a652-3e4d4a06848f","acronym":"","url":"https://clinicaltrials.gov/study/NCT03347838","created_at":"2023-11-29T17:14:43.874Z","updated_at":"2025-02-25T14:37:43.448Z","phase":"Phase 2","brief_title":"Nivolumab for the Reversal of Squamous Dysplasia in High Risk Current and Former Smokers","source_id_and_acronym":"NCT03347838","lead_sponsor":"University of Colorado, Denver","biomarkers":" PD-L1 • PD-1 • CD4 • CD68 • HLA-DRA • MRC1","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1 • PD-1 • CD4 • CD68 • HLA-DRA • MRC1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 36","initiation":"Initiation: 01/30/2019","start_date":" 01/30/2019","primary_txt":" Primary completion: 12/01/2025","primary_completion_date":" 12/01/2025","study_txt":" Completion: 12/01/2026","study_completion_date":" 12/01/2026","last_update_posted":"2024-09-25"}]